Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL973654 | 0.91 | MEN1 (0.72) | MEN1LMNACYP3A4KMT2A | |
| SCHEMBL28429885 | 0.89 | — | — | |
| SCHEMBL972924 | 0.89 | MEN1 (0.73) | MEN1LMNACYP3A4KMT2A | |
| SCHEMBL190974 | 0.89 | MEN1 (0.73) | MEN1LMNACYP3A4KMT2A | |
| Phosphoric Acid SCHEMBL14775951 | 0.85 | MEN1 (0.68) | MEN1LMNACYP3A4KMT2A | |
| SCHEMBL974858 | 0.84 | MEN1 (0.67) | MEN1LMNACYP3A4KMT2A | |
| SCHEMBL972115 | 0.81 | MEN1 (0.72) | MEN1LMNACYP3A4KMT2A | |
| Oseltamivir SCHEMBL125557 | 0.80 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2A | |
| Oseltamivir SCHEMBL14283136 | 0.80 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2A | |
| Oseltamivir SCHEMBL14775954 | 0.80 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304553-B2 | Method of forming oseltamivir and derivatives thereof | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2012-11-06 | — | — | US | disclosed |
| US-20110021762-A1 | METHOD OF FORMING OSELTAMIVIR AND DERIVATIVES THEREOF | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021762-A1 | METHOD OF FORMING OSELTAMIVIR AND DERIVATIVES THEREOF | AOC1, ALK, ALDH3A1 | MEN1 4561/4885LMNA 3294/4885CYP3A4 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.